DayTwo, a Walnut Creek, Calif.-based precision nutrition company leveraging advanced proprietary microbiome science, raised $37m in funding.
The round, which brought total fundraise to $85m, was led by Cathay Innovation and aMoon. In conjunction with the funding, DayTwo also appointed John Watts, Jr., Chief Executive Officer of Paradigm, to its board of directors.
Led by new CEO David Henderson, a former founding executive member of Oscar Health, DayTwo is a precision nutrition company which leverages its most advanced proprietary microbiome science to offer a path to remission for metabolic diseases (diabetes, prediabetes, and clinical obesity). The solution includes gut microbiome profiling, artificial intelligence to predict blood sugar response to foods, and dedicated virtual care.
The company intends to use the funds to support the demand for its virtual care solution for metabolic diseases.